BBIO news

BridgeBio Pharma entered a voluntary agreement with the U.S. Administration to expand Medicaid access to its medicine without future pricing mandates, sustaining innovation. The announcement occurred at the White House and builds on existing patient support programs.

BridgeBio Pharma announced FDA acceptance of a new drug application for encaleret targeting autosomal dominant hypocalcemia type 1, setting a target action date of May 8, 2027, and representing a potential blockbuster opportunity for the company.

BridgeBio Pharma Inc filed a certificate designating 933,900 shares of Series A cumulative preferred stock. This corporate equity designation is a standard capitalization update with no immediate impact on operations.

BridgeBio Pharma filed a Third Amended and Restated 2021 Stock Option and Incentive Plan. The update aims to expand equity compensation opportunities to align key personnel interests with shareholder value.

Boundless Bio entered into a merger agreement with Serapha Bio to combine in an all-stock deal. Shareholder approval is required to complete the reorganization.

BridgeBio announced FDA acceptance of its New Drug Application for BBP-418 to treat LGMD2I/R9, a rare genetic muscular dystrophy, with a Priority Review designation and potential November 2026 approval. If approved, BBP-418 would be the first therapy for LGMD2I/R9 and the first approved treatment fo…